Covista Inc.
CVSA
$115.82
-12.33%
Covista Inc. is an American healthcare educator that serves over 97,000 students across five accredited institutions, addressing the U.S. healthcare workforce shortage through personalized, tech-enabled education. As a scaled operator in the for-profit education sector, Covista distinguishes itself by focusing exclusively on healthcare training, a niche with strong secular demand. The current investor narrative centers on the company's ability to sustain enrollment growth and margin expansion amid regulatory scrutiny and shifting student preferences, with recent quarterly results showing steady revenue gains and improved profitability.…
CVSA
Covista Inc.
$115.82
CVSA 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Covista Inc.'s 12-month outlook, with a consensus price target around $156.25 and implied upside of +34.9% versus the current price.
Average Target
$156.25
0 analysts
Implied Upside
+34.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$140 - $175
Analyst target range
Only one analyst covers Covista, with a consensus rating of Outperform/Buy. The average target price is not explicitly provided, but the estimated EPS average is $11.04, implying a forward P/E of 10.5x based on the current price of $115.82. This suggests significant upside if the earnings estimates are realized. The limited coverage implies the stock is underfollowed, which can lead to higher volatility and less efficient price discovery. The single analyst from Barrington Research has maintained an Outperform rating consistently since October 2025, indicating a stable positive view. Without a target price range, the implied upside cannot be precisely calculated, but the forward P/E of 13.03x versus the trailing 20.29x suggests the market is pricing in earnings growth that could drive the stock higher.
Drowning in data?
Find the real signal!
Bulls vs Bears: CVSA Investment Factors
Covista presents a mixed picture: strong free cash flow, consistent revenue growth, and a low PEG ratio suggest undervaluation, while net margin compression, limited analyst coverage, and a recent sharp price decline raise caution. The bull case is supported by the PEG ratio of 0.25x and FCF of $336M, but the bear case is strengthened by the margin drop and liquidity concerns. The single most important tension is whether the company can stabilize and improve its net margins; if margins recover, the stock could re-rate significantly, but if they continue to compress, the valuation premium may erode.
Bullish
- Undervalued on PEG ratio: The PEG ratio of 0.25x suggests the stock is deeply undervalued relative to its earnings growth. This is a strong indicator that the market is not fully pricing in the company's growth potential.
- Strong free cash flow generation: Trailing twelve-month free cash flow is $336.28 million, providing ample capacity for reinvestment, share buybacks, or debt reduction. This financial flexibility supports future growth and shareholder returns.
- Consistent revenue growth: Revenue grew 4.5% year-over-year in Q3 2026, with sequential growth from $457.11 million in Q4 2025 to $503.39 million in Q2 2026. The healthcare education niche benefits from strong secular demand.
- Low beta offers downside protection: With a beta of 0.616, the stock is less volatile than the market, appealing to risk-averse investors. This characteristic can help preserve capital during market downturns.
Bearish
- Net margin compression: Net margin declined from 15.2% in Q2 2026 to 8.5% in Q3 2026, a significant drop. This raises concerns about cost control and profitability sustainability.
- Limited analyst coverage: Only one analyst covers the stock, leading to less efficient price discovery and potentially higher volatility. The lack of consensus makes it harder to gauge market sentiment.
- Recent price decline from highs: The stock is down 16.29% over the past year and recently dropped 12.33% in a single day (July 15, 2026). This negative momentum could persist if fundamentals deteriorate.
- Low current ratio: The current ratio of 0.82 indicates potential liquidity risk, as current liabilities exceed current assets. This could strain the company's ability to meet short-term obligations.
CVSA Technical Analysis
The stock is in a broad uptrend over the past year, with a 1-year price change of -16.29% reflecting a pullback from its 52-week high of $156.26. Currently trading at $115.82, the stock sits at 74% of its 52-week range, suggesting it is well off the highs but still above the 52-week low of $86.97. This positioning indicates a correction within a longer-term uptrend, potentially offering a value entry if the trend resumes. Short-term momentum is mixed: the 1-month price change is -1.56%, while the 3-month change is -0.16%, showing a deceleration from the longer-term trend. The 1-month decline contrasts with the 1-year negative return, signaling a potential short-term stabilization or consolidation phase. The stock's beta of 0.616 indicates it is less volatile than the market, which may appeal to risk-averse investors. Key support is at the 52-week low of $86.97, while resistance is at the 52-week high of $156.26. A breakout above $156.26 would signal a resumption of the uptrend, while a breakdown below $86.97 could indicate further downside. The low beta suggests the stock may not participate fully in market rallies but also offers downside protection.
Beta
0.62
0.62x market volatility
Max Drawdown
-14.6%
Largest decline past year
52-Week Range
$87-$156
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CVSA Return | S&P 500 |
|---|---|---|
| 1m | -1.6% | +0.6% |
| 3m | -0.2% | +6.3% |
| 6m | — | +9.1% |
| 1y | — | +20.9% |
| ytd | — | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CVSA Fundamental Analysis
Revenue has grown steadily, with the most recent quarter (Q3 2026) reporting $487.03 million, up 4.5% year-over-year from $466.06 million in Q3 2025. The multi-quarter trend shows consistent sequential growth from $457.11 million in Q4 2025 to $503.39 million in Q2 2026, though Q3 2026 saw a slight dip from Q2. The growth is driven by the healthcare education segment, which benefits from strong demand for skilled workers. Profitability is solid: net income in Q3 2026 was $41.64 million, with a net margin of 8.5%, down from 15.2% in Q2 2026 but still positive. Gross margin remains stable at 56.7%, while operating margin was 18.9%. The company is consistently profitable, with trailing twelve-month net income of $234.06 million. The balance sheet is healthy: debt-to-equity is 0.54, and the current ratio is 0.82, indicating adequate liquidity. Free cash flow for the trailing twelve months is $336.28 million, providing ample capacity for internal growth and share repurchases. ROE is 16.2%, reflecting efficient use of equity capital.
Quarterly Revenue
$487030000.0B
2026-03
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
56.7%
Latest Quarter
Free Cash Flow
$336279000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CVSA Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 20.29x, while the forward P/E is 13.03x, implying the market expects earnings growth. The gap between trailing and forward P/E suggests a significant earnings expansion is anticipated. Compared to the industry average (not provided, but based on typical consumer cyclical education peers), a trailing P/E of 20.29x appears reasonable given the company's growth and margins. The PEG ratio of 0.25x indicates the stock is undervalued relative to its earnings growth rate. Historically, the trailing P/E has ranged from 8.94x (Q3 2023) to 104.38x (Q1 2023), with the current 20.29x near the lower end of the historical band. This suggests the stock is not overvalued by its own standards and may offer a margin of safety, though the historical low P/E periods coincided with weaker profitability.
PE
20.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~23x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is net margin compression, which fell from 15.2% in Q2 2026 to 8.5% in Q3 2026, a decline of nearly 700 basis points. This could indicate rising costs or pricing pressure. Additionally, the current ratio of 0.82 suggests that current liabilities exceed current assets, posing a liquidity risk. The debt-to-equity ratio of 0.54 is moderate but not alarming. If margins continue to deteriorate, earnings could disappoint, leading to further multiple compression.
Market & Competitive Risks: The stock's beta of 0.616 implies lower market correlation, but it also means the stock may underperform in strong bull markets. The for-profit education sector faces regulatory scrutiny, which could impact enrollment and revenue. With only one analyst covering the stock, there is a risk of sudden price moves on any news. The recent 12.33% one-day drop on July 15, 2026, highlights vulnerability to negative sentiment. The 52-week high of $156.26 is 35% above the current price, indicating significant upside potential but also the risk of a prolonged downtrend.
Worst-Case Scenario: In a worst-case scenario, continued margin compression, regulatory headwinds, and a broader market downturn could drive the stock to its 52-week low of $86.97, representing a 25% decline from the current price of $115.82. If earnings miss estimates and the single analyst downgrades, the stock could fall further. The historical max drawdown of -14.56% suggests that such a decline is within the realm of possibility, but a 25% drop to the 52-week low is a realistic downside.
